ArticleJournal of cancer research and clinical oncology2011
Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach.
Article in Journal of cancer research and clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- The Role of CAF-derived Vitronectin in Promoting Colorectal Cancer Progression and Immunosuppression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Identification of vitronectin as a potential non-invasive biomarker of metastatic breast cancer using a label-free LC-MS/MS approach.Breast cancer research : BCR · 2025Article
- Characterization of Vitronectin Effect in 3D Ewing Sarcoma Models: A Digital Microscopic Analysis of Two Cell Lines.Cancers · 2024Article
- Vitronectin Levels in the Plasma of Neuroblastoma Patients and Culture Media of 3D Models: A Prognostic Circulating Biomarker?International journal of molecular sciences · 2024Article
- Identifying the key hub genes linked with lung squamous cell carcinoma by examining the differentially expressed and survival genes.Molecular genetics and genomics : MGG · 2024Article
- Small Extracellular Vesicles Promote Stiffness-mediated Metastasis.Cancer research communications · 2024Article
- Bioinformatic analysis of cancer-associated fibroblast related gene signature as a predictive model in clinical outcomes and immune characteristics of gastric cancer.Annals of translational medicine · 2022Article
- Dimeric and Multimeric DNA Aptamers for Highly Effective Protein Recognition.Molecules (Basel, Switzerland) · 2020Review
- Functional role of vitronectin in breast cancer.PloS one · 2020Article
- Clinical Proteomics Profiling for Biomarker Identification Among Patients Suffering With Indian Post Kala Azar Dermal Leishmaniasis.Frontiers in cellular and infection microbiology · 2020Article
- Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion.Breast cancer research : BCR · 2018Article
- Assessment of Vitronectin, Soluble Epithelial-Cadherin and TGF-β1 as a Serum Biomarker with Predictive Value for Endometrial and Ovarian Cancers.Turkish journal of pharmaceutical sciences · 2017Article
- Selection of a Novel Aptamer Against Vitronectin Using Capillary Electrophoresis and Next Generation Sequencing.Molecular therapy. Nucleic acids · 2016Article
- Vitronectin: a promising breast cancer serum biomarker for early diagnosis of breast cancer in patients.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach.PloS one · 2015Article
- Screening and functional analysis of a differential protein profile of human breast cancer.Oncology letters · 2014Article
- Proteomic profiling of the tumor microenvironment: recent insights and the search for biomarkers.Genome medicine · 2014Article
- Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.mAbs · 2014Review
- N-glycoprotein SRMAtlas: a resource of mass spectrometric assays for N-glycosites enabling consistent and multiplexed protein quantification for clinical applications.Molecular & cellular proteomics : MCP · 2013Article
- Breast tumor and stromal cell responses to TGF-β and hypoxia in matrix deposition.Matrix biology : journal of the International Society for Matrix Biology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBreast cancer is the most frequent malignancy in women. However, no useful serum markers with high sensitivity and specificity for the detection of early breast cancer have been identified. The search for biological markers of early breast cancer is of continual interest in experimental and clinical breast cancer research. We recently described a simple and highly reproducible three-step proteome analysis for identifying potential disease-marker candidates among the low-abundance serum proteins.
methodsSerum samples from breast ductal carcinoma in situ (DCIS) patients and normal controls were subjected to a three-step serum proteome analysis. The steps were the following: first, immunodepletion of most abundant proteins; second, fractionation using reverse-phase high-performance liquid chromatography; and third, separation using two-dimensional electrophoresis (2-DE). Differences revealed by protein staining were further confirmed by Western blotting, immunohistochemical staining, and enzyme-linked immunosorbent assays (ELISA).
resultsTwenty-two upregulated and 26 downregulated spots were detected on the 2-DE gels, and a total of 33 proteins were identified by liquid chromatography and tandem mass spectrometry. Western blotting confirmed that the level of vitronectin was significantly increased in DCIS patients compared with that of normal controls. Immunohistochemical staining of vitronectin in breast cancer tissue revealed high expression in small vessel walls surrounding cancer cells and the extracellular matrix of stroma. Moreover, vitronectin serum concentrations, as measured by ELISA, were significantly increased in patients with DCIS or more advanced breast cancer compared with those of normal controls.
conclusionsVitronectin could serve as a promising serum marker for the detection of primary breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.